Back to today’s briefing

Story perspectives

FDA Approves Bayer's Vitrakvi: A Game Changer for Cancer Treatment

4/12/2025

37 5

Summary

Story summary

Bayer's Vitrakvi (larotrectinib) has officially received FDA approval for treating solid tumors with NTRK gene fusions in both adults and children. This groundbreaking TRK inhibitor, which effectively targets tumors without resistance mutations, boasts a remarkable 60% overall response rate in trials. LUNGevity's CEO hailed this decision as a monumental leap forward in cancer treatment options.

1 of 1

Story summary

Bayer's Vitrakvi (larotrectinib) has officially received FDA approval for treating solid tumors with NTRK gene fusions in both adults and children. This groundbreaking TRK inhibitor, which effectively targets tumors without resistance mutations, boasts a remarkable 60% overall response rate in trials. LUNGevity's CEO hailed this decision as a monumental leap forward in cancer treatment options.